Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Attikon Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with high grade serous ovarian cancer treated with chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Assessment of elements of adaptive immunity in tumor biopsies | Other | Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated at tumor biopsies of patients with advanced ovarian cancer treated with chemotherapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies | through study completion, an average of 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma cells (4-tiered score) | 3- years time frame (upon study completion) | |
| PD-L1 score (TPS score) in tumor biopsies | upon study completion (3 years) | |
| CD8 cells (low : <5 cells/HPF vs high (> 5 cells/HPF) expression) in tumor biopsies |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
-Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hellenic Cooperative Oncology Group | Athens | Greece |
Not provided
| ID | Term |
|---|---|
| D000072717 | Tertiary Lymphoid Structures |
| ID | Term |
|---|---|
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
| upron study completion (3 years) |
| p53 (presence, absence) in tumor biopsies (immunohistochemistry) | upon study compeltion (3 years) |